Curis Lifesciences Reports FY26 Revenue Growth of 21.16%; Strategic Investments Bolster Long-Term Expansion Plan

Curis Lifesciences Reports FY26 Revenue Growth of 21.16%; Strategic Investments Bolster Long-Term Expansion Plan​

Ahmedabad, India | June 23, 2026

Curis Lifesciences Limited, a pharmaceutical and healthcare products company, reported substantial revenue growth during the financial year (FY) 2026. The Company achieved total revenue of 6,062.88 Lakhs, marking a 21.16% increase year-over-year. For FY26, Curis also recorded an EBITDA of 1,141.09 Lakhs and a Profit After Tax (PAT) of 691.64 Lakhs.

Despite achieving strong top-line growth, management noted that profitability margins were affected during the year due to strategic growth investments, temporary raw material cost pressures, and certain one-time expenses. However, the company expressed confidence that these factors will support long-term value creation and are already showing signs of normalization.

Operational Highlights and Market Strategy​

Curis Lifesciences focused on several initiatives throughout FY26 aimed at strengthening its foundation for future growth. A key strategic move involved expansion into the Nigerian market through its Eurosun Joint Venture (JV). As part of this market-entry strategy, products were initially offered at lower margins to establish customer relationships, gain brand recognition, and secure market share. The company reported that margin improvements in these newly penetrated markets have begun and are expected to progressively move toward normalized levels.

Furthermore, the company experienced a sharp increase in certain raw material costs during February and March 2026. Subsequent pricing revisions and stabilization in input costs have since led to margin recovery, bringing profitability trends closer to historical levels.

Key Financial Performance Metrics​

The financial health of Curis Lifesciences demonstrated diversification across its operational metrics for FY26 and the preceding periods. The consolidated performance details are presented below:

Management Perspective and Future Outlook​

Mr. Dharmesh Patel, Chairman and Managing Director of Curis Lifesciences Limited, stated that FY26 was characterized by strategic investments and platform building for the company. While noting material inflation and one-time expenses, he confirmed that these initiatives were undertaken with a long term growth perspective. He expressed satisfaction with the strong revenue growth achieved during the year and highlighted that many factors impacting margins have already started normalizing, helping to create value for all stakeholders.

The Company's future outlook remains focused on sustainable growth by strengthening its position in both domestic and international markets. Growth is expected to be supported by several factors: margin normalization in newly penetrated export markets; benefits derived from the acquisition and integration of Uninova Lifesciences; increased contribution from the Nigerian business via the Eurosun JV; and continued expansion of own brand products alongside the international business.

CURIS Stock Price Movement​

Shares of Curis Lifesciences Limited slipped today by 2.75% to settle at ₹106.00, down from the previous close. The stock traded on a volume of 2,000 shares after opening at ₹106.50.